TY - JOUR
T1 - Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma
AU - For the Fukuoka Blood and Marrow Transplantation Group
AU - Yamasaki, Satoshi
AU - Yoshida, Shuro
AU - Kato, Koji
AU - Choi, Ilseung
AU - Imamura, Yutaka
AU - Kohno, Kentaro
AU - Henzan, Hideho
AU - Tanimoto, Kazuki
AU - Ogawa, Ryosuke
AU - Suehiro, Youko
AU - Miyamoto, Toshihiro
AU - Eto, Tetsuya
AU - Ohshima, Koichi
AU - Akashi, Koichi
AU - Iwasaki, Hiromi
N1 - Funding Information:
We thank the patients and clinical staff for their participation in the study. We appreciate Akishiko Numata, Goichi Yoshimoto, Yasuo Mori (Kyushu University Hospital), Takuro Kuriyama, Yayoi Matsuo, Masayasu Hayashi, and Tomonori Shimokawa (Hamanomachi Hospital) for checking the medical records. The authors also acknowledge the Clinical Research Institute, Kyushu Medical Hospital for editorial support. We thank Edanz Group (www.edanzediting.com/ac ) for editing a draft of this manuscript. All named authors meet the International Committee of Medical Journal Editors criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Funding Information:
No funding or sponsorship was received for this study or publication of this article. The article processing charges were funded by the authors. Acknowledgments
Publisher Copyright:
© 2020, Japanese Society of Hematology.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - The effects of stem cell transplantation (SCT) in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) remain controversial. We analyzed the feasibility of SCT and risk factors associated with outcomes of PTCL-NOS and AITL patients to identify the potential clinical efficacy of SCT. We retrospectively analyzed the data of PTCL-NOS (n = 83) and AITL (n = 112) patients who received autologous (n = 10 and 16, respectively) or allogeneic (n = 12 and 4, respectively) SCT, or no SCT (n = 61 and 92, respectively) between 2008 and 2018. All PTCL-NOS and AITL diagnoses were reconfirmed by an experienced hematopathologist. Median age at PTCL-NOS and AITL diagnoses in the SCT group was younger than that in the no SCT group. Significant risk factors for lower overall survival were intermediate–high and high-risk international prognostic indexes in PTCL-NOS patients (P = 0.0052), and a > 2 modified prognostic index for T-cell lymphoma (P = 0.0079) and no SCT (P = 0.028) in AITL patients. Autologous or allogeneic SCT compared with no SCT in AITL patients resulted in 3-year overall survival of 68.6% and 100% vs. 57.2% (P = 0.018). Strategies should be developed to improve selection of PTCL-NOS and AITL patients suitable for SCT and/or additional novel therapies.
AB - The effects of stem cell transplantation (SCT) in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) remain controversial. We analyzed the feasibility of SCT and risk factors associated with outcomes of PTCL-NOS and AITL patients to identify the potential clinical efficacy of SCT. We retrospectively analyzed the data of PTCL-NOS (n = 83) and AITL (n = 112) patients who received autologous (n = 10 and 16, respectively) or allogeneic (n = 12 and 4, respectively) SCT, or no SCT (n = 61 and 92, respectively) between 2008 and 2018. All PTCL-NOS and AITL diagnoses were reconfirmed by an experienced hematopathologist. Median age at PTCL-NOS and AITL diagnoses in the SCT group was younger than that in the no SCT group. Significant risk factors for lower overall survival were intermediate–high and high-risk international prognostic indexes in PTCL-NOS patients (P = 0.0052), and a > 2 modified prognostic index for T-cell lymphoma (P = 0.0079) and no SCT (P = 0.028) in AITL patients. Autologous or allogeneic SCT compared with no SCT in AITL patients resulted in 3-year overall survival of 68.6% and 100% vs. 57.2% (P = 0.018). Strategies should be developed to improve selection of PTCL-NOS and AITL patients suitable for SCT and/or additional novel therapies.
UR - http://www.scopus.com/inward/record.url?scp=85083451828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083451828&partnerID=8YFLogxK
U2 - 10.1007/s12185-020-02879-w
DO - 10.1007/s12185-020-02879-w
M3 - Article
C2 - 32297159
AN - SCOPUS:85083451828
VL - 112
SP - 74
EP - 83
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 1
ER -